Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

被引:10
作者
Emens, Leisha A. [1 ]
机构
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA
关键词
breast cancer immunity; breast cancer vaccine; clinical trials; immune checkpoint blockade; immune tolerance; immunotherapy; tumor microenvironment; GROUP-STUDY I-01; REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; HER2/NEU PEPTIDE E75; I CLINICAL-TRIAL; METASTATIC BREAST; PHASE-I; DENDRITIC CELLS; EARLY-STAGE; PERIPHERAL-BLOOD;
D O I
10.1586/ERA.12.147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is immunogenic, and infiltrating immune cells in primary breast tumors convey important clinical prognostic and predictive information. Furthermore, the immune system is critically involved in clinical responses to some standard cancer therapies. Early breast cancer vaccine trials have established the safety and bioactivity of breast cancer immunotherapy, with hints of clinical activity. Novel strategies for modulating regulators of immunity, including regulatory T cells, myeloid-derived suppressor cells and immune checkpoint pathways (monoclonal antibodies specific for the cytotoxic T-lymphocyte antigen-4 or programmed death), are now available. In particular, immune checkpoint blockade has enormous therapeutic potential. Integrative breast cancer immunotherapies that strategically combine established breast cancer therapies with breast cancer vaccines, immune checkpoint blockade or both should result in durable clinical responses and increased cures.
引用
收藏
页码:1597 / 1611
页数:15
相关论文
共 129 条
[1]   Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21 [J].
Adluri, S ;
Gilewski, T ;
Zhang, S ;
Ramnath, V ;
Ragupathi, G ;
Livingston, P .
BRITISH JOURNAL OF CANCER, 1999, 79 (11-12) :1806-1812
[2]   Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine:: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 [J].
Amin, Asna ;
Benavides, Linda C. ;
Holmes, Jarrod P. ;
Gates, Jeremy D. ;
Carmichael, Mark G. ;
Hueman, Matthew T. ;
Mittendorf, Elizabeth A. ;
Storrer, Catherine E. ;
Jama, Yusuf H. ;
Craig, Dianna ;
Stojadinovic, Alex ;
Ponniah, Sathibalan ;
Peoples, George E. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (12) :1817-1825
[3]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[4]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[5]   Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses [J].
Avigan, D ;
Vasir, B ;
Gong, JL ;
Borges, V ;
Wu, ZK ;
Uhl, L ;
Atkins, M ;
Mier, J ;
McDermott, D ;
Smith, T ;
Giallambardo, N ;
Stone, C ;
Schadt, K ;
Dolgoff, J ;
Tetreault, JC ;
Villarroel, M ;
Kufe, D .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4699-4708
[6]   Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells [J].
Baratelli, F ;
Lin, Y ;
Zhu, L ;
Yang, SC ;
Heuzé-Vourc'h, N ;
Zeng, G ;
Reckamp, K ;
Dohadwala, M ;
Sharma, S ;
Dubinett, SM .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1483-1490
[7]   The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 [J].
Benavides, Linda C. ;
Gates, Jeremy D. ;
Carmichael, Mark G. ;
Patel, Ritesh ;
Holmes, Jarrod P. ;
Hueman, Matthew T. ;
Mittendorf, Elizabeth A. ;
Craig, Dianna ;
Stojadinovic, Alexander ;
Ponniah, Sathibalan ;
Peoples, George E. .
CLINICAL CANCER RESEARCH, 2009, 15 (08) :2895-2904
[8]   High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo [J].
Benzaid, Ismahene ;
Moenkkoenen, Hannu ;
Stresing, Verena ;
Bonnelye, Edith ;
Green, Jonathan ;
Moenkkoenen, Jukka ;
Touraine, Jean-Louis ;
Clezardin, Philippe .
CANCER RESEARCH, 2011, 71 (13) :4562-4572
[9]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[10]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175